SCHEMBL4052401

SCHEMBL4052401

Fc1ccc(-c2cc3[nH][c]nn3n2)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALPL P05186 3/20 0.35
F2RL3 Q96RI0 1/20 0.35
KMO O15229 2/20 0.35
GRM5 P41594 2/20 0.34
TGFBR1 P36897 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C8 P10632 1/20 0.33
TP53 P04637 2/20 0.33
MDM2 Q00987 2/20 0.33
PDE10A Q9Y233 1/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
GABRA3 P34903 2/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
ESR1 P03372 1/20 0.30
MDM4 O15151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052774 0.90 TGFBR1 (0.31) GRM5TGFBR1CYP3A4CYP2C8
SCHEMBL4052659 0.84 ADORA3 (0.39) F2RL3TGFBR1CYP1A2CYP3A4
SCHEMBL4045189 0.80 MEN1 (0.39) ALPLTP53
SCHEMBL4049910 0.77 GRM5 (0.34) GRM5CYP1A2
SCHEMBL4046588 0.75 NISCH (0.32)
SCHEMBL4045655 0.72 JAK2 (0.40) CYP3A4
SCHEMBL4047454 0.72 IDO1 (0.39) ALPLCYP1A2CYP3A4TP53ADORA2A
SCHEMBL4047366 0.71 CYP1A2 (0.39) F2RL3KMOTGFBR1CYP1A2CYP3A4
SCHEMBL4051538 0.68 RAD51 (0.39) F2RL3GRM5
SCHEMBL2752212 0.66 F2RL3 (0.41) ALPLF2RL3KMOGRM5TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R ALPL 3498/4885F2RL3 1971/4885KMO 175/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R ALPL 3549/4885F2RL3 1806/4885KMO 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.